Clinical Trial Update: A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating custirsen added to docetaxel retreatment or cabazitaxel as second-line therapy for metastatic castration-resistant prostate cancer ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• Custirsen (custirsen)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Achieve Life Sciences | Conditions: Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 3 | Status: TERMINATED